Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its access have become key topics for patients and healthcare practitioners. While tirzepatide has been approved by regulatory agencies, its expensive nature presents a significant obstacle to many.